CD22 as a target of passive immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CD22 is a B-cell restricted sialoglycoprotein expressed on mature B-cells.
• Its precise function is under investigation, with proposed roles in B-cell activation and adhesion.
• CD22 plays a critical role in B-cell development, survival, and apoptosis.

Purpose of the Study:

• To investigate the role of CD22 in B-cell biology and its potential as a therapeutic target.
• To evaluate the efficacy of anti-CD22 monoclonal antibodies in B-cell malignancies.

Main Methods:

• Analysis of CD22 expression in normal and malignant B-cells.
• Studies in CD22-deficient mice to assess its role in B-cell development.
• Preclinical evaluation of anti-CD22 antibodies (naked, toxin-labeled, radiolabeled) for immunotherapy.
• Clinical trials of a humanized naked anti-CD22 antibody (epratuzumab) in non-Hodgkin's lymphoma (NHL).

Main Results:

• CD22 deficiency in mice leads to reduced mature B-cells, shorter lifespan, and increased apoptosis.
• CD22 internalization upon ligand binding provides costimulatory or proapoptotic signals.
• Preclinical studies demonstrate CD22 as an effective target for B-cell malignancy immunotherapy.
• Ongoing clinical trials show eprauzumab, alone or in combination, to be effective and well-tolerated in NHL patients.

Conclusions:

• CD22 is essential for B-cell development and survival.
• Anti-CD22 monoclonal antibodies represent a promising therapeutic strategy for B-cell malignancies.
• Epratuzumab shows clinical efficacy and tolerability in NHL treatment.